Orthocell Ltd Asset Resilience Ratio
Orthocell Ltd asset resilience ratio. Orthocell Ltd (OCC) has an Asset Resilience Ratio of 81.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OCC defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Orthocell Ltd (2017–2025)
Asset resilience ratio of Orthocell Ltd from 2017 to 2025. This chart shows how Orthocell Ltd's Asset Resilience Ratio has changed over time. Read OCC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Orthocell Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Orthocell Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$28.62 Million | 81.22% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$28.62 Million | 81.22% |
Asset Resilience Insights
- Very High Liquidity: Orthocell Ltd maintains exceptional liquid asset reserves at 81.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Orthocell Ltd Industry Peers by Asset Resilience Ratio
Compare Orthocell Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Orthocell Ltd Asset Resilience Ratio by Year (2017–2025)
Orthocell Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Orthocell Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 75.20% | AU$26.50 Million ≈ $18.75 Million |
AU$35.24 Million ≈ $24.93 Million |
-2.25pp |
| 2024-06-30 | 77.45% | AU$20.61 Million ≈ $14.59 Million |
AU$26.62 Million ≈ $18.83 Million |
-6.38pp |
| 2023-06-30 | 83.83% | AU$24.82 Million ≈ $17.56 Million |
AU$29.61 Million ≈ $20.95 Million |
+54.75pp |
| 2022-06-30 | 29.08% | AU$11.02 Million ≈ $7.80 Million |
AU$37.90 Million ≈ $26.81 Million |
-55.39pp |
| 2021-06-30 | 84.47% | AU$16.33 Million ≈ $11.55 Million |
AU$19.33 Million ≈ $13.68 Million |
-3.75pp |
| 2020-06-30 | 88.22% | AU$20.44 Million ≈ $14.46 Million |
AU$23.17 Million ≈ $16.39 Million |
+5.59pp |
| 2019-06-30 | 82.63% | AU$11.24 Million ≈ $7.95 Million |
AU$13.60 Million ≈ $9.62 Million |
+26.99pp |
| 2018-06-30 | 55.65% | AU$2.91 Million ≈ $2.06 Million |
AU$5.23 Million ≈ $3.70 Million |
-14.84pp |
| 2017-06-30 | 70.49% | AU$5.05 Million ≈ $3.57 Million |
AU$7.16 Million ≈ $5.07 Million |
-- |
About Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more